Our results are supported by Zhu et al.’s report that the EGFR inhibitor UNC9995 inhibits LPS-induced astrocytic NLRP3 inflammasome and IL-1β levels in a mouse model of Parkinson’s disease (PD) (60). Here, NLRP3 is linked to Parkinson disease.